Chronic Myelogenous Leukemia Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (03/15/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview for Chronic Myelogenous Leukemia (CML)

Revised text to state that in a randomized trial comparing imatinib mesylate with interferon plus cytarabine, at 10.9 years' median follow-up, imatinib mesylate induced complete cytogenetic responses in 83% of newly diagnosed patients; in addition, the annual rate of progression to accelerated phase or blast crisis dropped from 2% to less than 1% in the fourth year on the imatinib arm (cited Hochhaus et al. as reference 2). Also revised text to state that although evidence-based survival advantages are unavailable because of crossover in randomized trials, the overall survival (OS) rate for all patients at 10 years is 83.3%, with fewer than 50% of all deaths caused by CML.

Chronic-Phase CML

Revised text to state that a trial randomly assigning 1,106 previously untreated patients to imatinib mesylate or to interferon plus cytarabine documented an 82.8% complete cytogenetic response rate with imatinib mesylate versus 14% for interferon plus cytarabine at a median follow-up of 10.9 years (cited Hochhaus et al. as reference 1). Also revised text to state that although evidence-based survival advantages are unavailable because of crossover in randomized trials, the OS rate for all patients at 10 years is 83.3%, with fewer than 50% of all deaths caused by CML.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Key References for CML

Next section >
About This PDQ Summary